These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 34218580)

  • 21. Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy.
    Xu Q; Shi Y; Xue L; An F; Xu H; Liu X; Zhu X; Sun Z; Zhai Z; Wang X
    Cell Transplant; 2023; 32():9636897231204724. PubMed ID: 37846503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
    Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
    Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia: An open-label pragmatic clinical trial.
    Jiang H; Li C; Yin P; Guo T; Liu L; Xia L; Wu Y; Zhou F; Ai L; Shi W; Lu X; Wang H; Tang L; Wei Q; Deng J; Jin R; Xiong W; Dong J; Mei H; Hu Y
    Am J Hematol; 2019 Oct; 94(10):1113-1122. PubMed ID: 31321805
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
    Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
    J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Report: Unedited allogeneic chimeric antigen receptor T cell bridging to conditioning-free hematopoietic stem cell transplantation for a child with refractory Burkitt lymphoma.
    Yang X; Luo C; Qian J; Huang X; Zhang J; Wang J; Luo C; Qin X; Li B; Chen J
    Front Immunol; 2023; 14():1219872. PubMed ID: 37736096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation.
    Chen Y; Cheng Y; Suo P; Yan C; Wang Y; Chen Y; Han W; Xu L; Zhang X; Liu K; Chang L; Xiao L; Huang X
    Br J Haematol; 2017 Nov; 179(4):598-605. PubMed ID: 29076142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Safety and efficacy of patients with refractory B-lymphoblastic leukemia treated with anti-CD19 CAR-T cell bridging to allogeneic hematopoietic stem cell transplantation].
    Ai H; Yin QS; Wang Q; Fu YW; Wei XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):239-244. PubMed ID: 32311895
    [No Abstract]   [Full Text] [Related]  

  • 28. Donor-derived Anti-CD19 CAR T cells GC007g for relapsed or refractory B-cell acute lymphoblastic leukemia after allogeneic HSCT: a phase 1 trial.
    Luo Y; Gao L; Liu J; Yang L; Wang L; Lai X; Gao S; Liu L; Zhao L; Ye Y; Wang M; Shen L; Cao WW; Wang D; Li W; Zhang X; Huang H
    EClinicalMedicine; 2024 Jan; 67():102377. PubMed ID: 38204488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study.
    Yang J; He J; Zhang X; Li J; Wang Z; Zhang Y; Qiu L; Wu Q; Sun Z; Ye X; Yin W; Cao W; Shen L; Sersch M; Lu P
    Blood Cancer J; 2022 Jul; 12(7):104. PubMed ID: 35798714
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant.
    Zhang C; Wang XQ; Zhang RL; Liu F; Wang Y; Yan ZL; Song YP; Yang T; Li P; Wang Z; Ma YY; Gao L; Liu Y; Gao L; Kong PY; Liu J; Tan X; Zhong JF; Chen YQ; Liang AB; Ren JH; Li ZY; Cao J; Gao QL; Zhou J; Gao Y; Zhang D; Fan FY; Han MZ; Gale RP; Zhang X
    Leukemia; 2021 Jun; 35(6):1563-1570. PubMed ID: 33077866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant.
    Li Q; Mu J; Yuan J; Yang Z; Wang J; Deng Q
    Onco Targets Ther; 2020; 13():11471-11484. PubMed ID: 33204102
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Safety and efficacy of humanized CD19-targeted CAR-T cells in patients with relapsed/refractory acute B cell lymphoblastic leukemia].
    Song FM; Hu YX; Zhang MM; Wu WW; Xu HJ; Zhang HS; Huang H; Wei GQ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):651-656. PubMed ID: 36709149
    [No Abstract]   [Full Text] [Related]  

  • 34. CD19+ lineage chimerism, an early biomarker after anti-CD19 CAR-T cell therapy in patients previously receiving a hematopoietic stem cell transplantation.
    Martínez-Romera I; Galán-Gómez V; González-Martínez B; Guerra García P; San Román Pacheco S; Corral Sánchez D; Mozo Del Castillo Y; Bueno Sánchez D; Sisinni L; González Guerrero A; Castellano Dámaso S; Sánchez Zapardiel E; Ruz Caracuel B; Balas Pérez A; Pérez-Martínez A
    Front Immunol; 2022; 13():960412. PubMed ID: 36003375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor-derived anti-CD19 CAR T cells compared with donor lymphocyte infusion for recurrent B-ALL after allogeneic hematopoietic stem cell transplantation.
    Hua J; Zhang J; Zhang X; Wu X; Zhou L; Bao X; Han Y; Miao M; Li C; Fu C; Chen S; Tang X; Wu D; Qiu H
    Bone Marrow Transplant; 2021 May; 56(5):1056-1064. PubMed ID: 33235353
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
    Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
    Front Immunol; 2022; 13():934442. PubMed ID: 36110859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features.
    Zhang X; Lu XA; Yang J; Zhang G; Li J; Song L; Su Y; Shi Y; Zhang M; He J; Song D; Lv F; Li W; Wu Y; Wang H; Liu H; Zhou X; He T; Lu P
    Blood Adv; 2020 May; 4(10):2325-2338. PubMed ID: 32453841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 39. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.
    Cruz CR; Micklethwaite KP; Savoldo B; Ramos CA; Lam S; Ku S; Diouf O; Liu E; Barrett AJ; Ito S; Shpall EJ; Krance RA; Kamble RT; Carrum G; Hosing CM; Gee AP; Mei Z; Grilley BJ; Heslop HE; Rooney CM; Brenner MK; Bollard CM; Dotti G
    Blood; 2013 Oct; 122(17):2965-73. PubMed ID: 24030379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial.
    Benjamin R; Jain N; Maus MV; Boissel N; Graham C; Jozwik A; Yallop D; Konopleva M; Frigault MJ; Teshima T; Kato K; Boucaud F; Balandraud S; Gianella-Borradori A; Binlich F; Marchiq I; Dupouy S; Almena-Carrasco M; Pannaux M; Fouliard S; Brissot E; Mohty M;
    Lancet Haematol; 2022 Nov; 9(11):e833-e843. PubMed ID: 36228643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.